NasdaqGS:BIIBBiotechs
Biogen (BIIB) Valuation Check After FDA Breakthrough Therapy Designation For Litifilimab
Biogen (BIIB) is back in focus after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its investigational drug litifilimab for cutaneous lupus erythematosus, highlighting renewed regulatory attention on its pipeline.
See our latest analysis for Biogen.
Biogen’s latest FDA updates come after a 19.93% 90 day share price return and a 25.82% 1 year total shareholder return. However, 3 and 5 year total shareholder returns remain sharply negative, suggesting recent...